David Risinger
Stock Analyst at Leerink Partners
(4.54)
# 283
Out of 4,761 analysts
168
Total ratings
65.17%
Success rate
15.64%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $700.33 | +19.09% | 8 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $182 → $169 | $162.30 | +4.13% | 3 | Jan 23, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $202.08 | +1.94% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $55.83 | +30.75% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $29.54 | +133.58% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $6.75 | +137.04% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $11.02 | +299.27% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $79.74 | +91.87% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $9.32 | +7.35% | 3 | Aug 6, 2024 | |
| HLVX HilleVax | Downgrades: Market Perform | $28 → $2 | $1.83 | +9.29% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $18.59 | +152.82% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $303.01 | +4.95% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $16.63 | -33.85% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $873.68 | -47.58% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $57.75 | -27.27% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $374 → $365 | $484.24 | -24.62% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $109.95 | -17.24% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $26.30 | +82.51% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $10.68 | -6.37% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $13.17 | -24.07% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $15.49 | +138.86% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $136.01 | +29.40% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $11.25 | +42.22% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $25.34 | +77.58% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $7.31 | +378.80% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $11.02 | +272.05% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $160.46 | +8.44% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $33.42 | +52.60% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $16.74 | -52.21% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $89.50 | -0.56% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $7.83 | -61.69% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $35.32 | -54.70% | 9 | Apr 2, 2020 |
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $700.33
Upside: +19.09%
Johnson & Johnson
Jan 23, 2025
Maintains: Outperform
Price Target: $182 → $169
Current: $162.30
Upside: +4.13%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $202.08
Upside: +1.94%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $55.83
Upside: +30.75%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $29.54
Upside: +133.58%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $6.75
Upside: +137.04%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $11.02
Upside: +299.27%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $79.74
Upside: +91.87%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $9.32
Upside: +7.35%
HilleVax
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.83
Upside: +9.29%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $18.59
Upside: +152.82%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $303.01
Upside: +4.95%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $16.63
Upside: -33.85%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $873.68
Upside: -47.58%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $57.75
Upside: -27.27%
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $484.24
Upside: -24.62%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $109.95
Upside: -17.24%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $26.30
Upside: +82.51%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $10.68
Upside: -6.37%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $13.17
Upside: -24.07%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $15.49
Upside: +138.86%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $136.01
Upside: +29.40%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $11.25
Upside: +42.22%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $25.34
Upside: +77.58%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $7.31
Upside: +378.80%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $11.02
Upside: +272.05%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $160.46
Upside: +8.44%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $33.42
Upside: +52.60%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $16.74
Upside: -52.21%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $89.50
Upside: -0.56%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $7.83
Upside: -61.69%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $35.32
Upside: -54.70%